Gao Ling
Department of Clinical Medicine, Zhengzhou Health College, Zhengzhou, 450000, China.
J Cardiothorac Surg. 2025 Jul 14;20(1):295. doi: 10.1186/s13019-025-03449-z.
To explore the clinical efficacy of nicorandil in treating elderly angina pectoris with diabetes mellitus (DM) and coronary heart disease (CHD), and the effect on improving vascular endothelial function (VEF).
110 elderly diabetic patients with CHD and angina pectoris who were treated in our hospital from April 2019 to March 2022 were chose as samples. All the subjects were distributed into 2 groups, namely A and B, and 55 people in each. B group were treated with secondary preventive drugs for CHD, and the A group were treated with nicorandil and secondary preventive drugs for CHD. After one month, the clinical efficacy, prethrombotic state, VEF, inflammatory factor levels, cardiac function were compared.
The bg, DD, PAI-1, vWF, ET-1, TNF-α and hs-CRP in A group after the treatment were below those in B (P < 0.05), t-PA, FMD, The NO content was significantly exceeded that of the B group. The LVEF and RHI indexes in A were exceed the data in B (P < 0.05), and the LVEDD and LVPWd were below the data in B (P < 0.05). The effective rate of clinical treatment in A was significantly exceed B's data.
Nicorandil can significantly improve angina pectoris in elderly patients with DM and CHD.
探讨尼可地尔治疗老年糖尿病合并冠心病心绞痛的临床疗效及对改善血管内皮功能的影响。
选取2019年4月至2022年3月在我院治疗的110例老年糖尿病合并冠心病心绞痛患者作为样本。所有受试者分为A、B两组，每组55人。B组采用冠心病二级预防药物治疗，A组采用尼可地尔联合冠心病二级预防药物治疗。1个月后，比较两组的临床疗效、血栓前状态、血管内皮功能、炎症因子水平、心功能。
治疗后A组的bg、DD、PAI-1、vWF、ET-1、TNF-α和hs-CRP低于B组（P＜0.05），t-PA、FMD、NO含量显著高于B组。A组的LVEF和RHI指数高于B组（P＜0.05），LVEDD和LVPWd低于B组（P＜0.05）。A组临床治疗有效率显著高于B组。
尼可地尔可显著改善老年糖尿病合并冠心病患者的心绞痛症状。
